Item Type | Name |
Concept
|
Hemangioma, Cavernous
|
Concept
|
Hemangioma, Cavernous, Central Nervous System
|
Academic Article
|
Vascular permeability in cerebral cavernous malformations.
|
Academic Article
|
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.
|
Academic Article
|
B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.
|
Academic Article
|
Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.
|
Academic Article
|
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
|
Academic Article
|
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.
|
Academic Article
|
Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.
|
Academic Article
|
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.
|
Academic Article
|
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
|
Academic Article
|
Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice.
|
Academic Article
|
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).
|
Academic Article
|
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.
|
Academic Article
|
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
|
Academic Article
|
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.
|
Academic Article
|
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease.
|
Academic Article
|
A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis.
|
Academic Article
|
Biomarkers of cavernous angioma with symptomatic hemorrhage.
|
Academic Article
|
A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.
|
Academic Article
|
Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations.
|
Academic Article
|
Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.
|
Academic Article
|
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature.
|
Academic Article
|
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance.
|
Academic Article
|
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.
|
Academic Article
|
Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma.
|
Academic Article
|
Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation.
|
Academic Article
|
Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.
|
Academic Article
|
Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models.
|
Academic Article
|
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
|
Academic Article
|
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
|
Academic Article
|
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.
|
Academic Article
|
Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.
|
Academic Article
|
Cerebral Cavernous Malformation: From Mechanism to Therapy.
|
Academic Article
|
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation.
|
Academic Article
|
Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.
|
Academic Article
|
Propranolol as therapy for cerebral cavernous malformations: a cautionary note.
|
Academic Article
|
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.
|
Academic Article
|
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma.
|
Academic Article
|
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation.
|
Academic Article
|
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling.
|
Academic Article
|
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.
|
Academic Article
|
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome.
|
Academic Article
|
Transcriptomic signatures of individual cell types in cerebral cavernous malformation.
|